SCHEMBL5657376

SCHEMBL5657376

CCNC(=O)C(c1ccccc1)(c1ccccc1)C1CCNC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
CYP2D6 P10635 1/20 0.43
HRH1 P35367 1/20 0.43
SCN1A P35498 1/20 0.43
KMT2A Q03164 1/20 0.43
SCN2A Q99250 1/20 0.43
SCN3A Q9NY46 1/20 0.43
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
SSTR4 P31391 2/20 0.40
SSTR1 P30872 1/20 0.40
CHRM2 P08172 4/20 0.39
CHRM1 P11229 4/20 0.39
CHRM3 P20309 4/20 0.39
ACSS2 Q9NR19 1/20 0.36
JAK3 P52333 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10361029 0.86 MC4R (0.49) MEN1LMNACYP2D6HRH1SCN1A
SCHEMBL13601291 0.80 MEN1 (0.50) MEN1LMNACYP2D6HRH1SCN1A
SCHEMBL14044375 0.80 CYP2D6 (0.46) MEN1LMNACYP2D6HRH1SCN1A
SCHEMBL953947 0.77 KMT2A (0.50) MEN1LMNACYP2D6HRH1SCN1A
SCHEMBL4396455 0.77 KMT2A (0.50) MEN1LMNACYP2D6HRH1SCN1A
SCHEMBL958241 0.77 KMT2A (0.50) MEN1LMNACYP2D6HRH1SCN1A
SCHEMBL11829368 0.77 HTT (0.40) CYP2D6CHRM2CHRM1CHRM3ACSS2
SCHEMBL963408 0.77 MEN1 (0.46) MEN1LMNACYP2D6HRH1SCN1A
Bromide SCHEMBL4505514 0.76 KMT2A (0.49) MEN1LMNACYP2D6HRH1SCN1A
Hydrochloric Acid SCHEMBL10869034 0.76 KMT2A (0.49) MEN1LMNACYP2D6HRH1SCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250414-B2 Diphenylmethyl compounds useful as muscarinic receptor antagonists THERAVANCE, INC. (US) 2007-07-31 US disclosed
EP-1615881-A2 DIARYLMETHYL AND RELATED COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY Theravance, Inc. (US) 2006-01-18 EP disclosed
US-20050203167-A1 Diphenylmethyl compounds useful as muscarinic receptor antagonists THERAVANCE, INC. 2005-09-15 US disclosed
WO-2004089892-A2 DIARYLMETHYL AND RELATED COMPOUNDS HAVING BETA2 ANDRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY THERAVANCE, INC. (US) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203167-A1 Diphenylmethyl compounds useful as muscarinic receptor antagonists CHRM1, CHRM2, CHRM3 MEN1 1011/4885LMNA 1646/4885CYP2D6 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.